Market: NMS |
Currency: USD
Address: 1717 Langhorne Newtown Road
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
📈 Savara Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$10.81
-
Upside/Downside from Analyst Target:
79.61%
-
Broker Call:
16
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2026-04-01
-
EPS Estimate:
-0.12
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Savara Inc.
| Date | Reported EPS |
|---|
| 2026-03-31 (estimated upcoming) | - |
| 2025-11-12 | -0.14 |
| 2025-08-13 | -0.14 |
| 2025-05-13 | -0.12 |
| 2025-03-27 | -0.13 |
| 2024-11-12 | -0.11 |
| 2024-08-12 | -0.12 |
| 2024-05-09 | -0.11 |
| 2024-03-07 | -0.09 |
| 2023-11-09 | -0.1 |
| 2023-08-10 | -0.07 |
| 2023-05-15 | -0.07 |
| 2023-03-30 | -0.07 |
| 2022-11-10 | -0.07 |
| 2022-08-11 | -0.06 |
| 2022-05-11 | -0.05 |
| 2022-03-30 | -0.07 |
| 2021-11-12 | -0.07 |
| 2021-08-12 | -0.07 |
| 2021-05-13 | -0.13 |
| 2021-03-10 | -0.23 |
| 2020-11-05 | -0.18 |
| 2020-08-06 | -0.16 |
| 2020-05-07 | -0.27 |
| 2020-03-12 | -0.28 |
📰 Related News & Research
No related articles found for "savara inc".
